Premium
Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma
Author(s) -
Park Yong Hyun,
Jung JinWoo,
Lee Byung Ki,
Lee Sangchul,
Jeong Seong Jin,
Byun SeokSoo,
Lee Sang Eun
Publication year - 2015
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.12662
Subject(s) - medicine , metastasectomy , renal cell carcinoma , targeted therapy , metastasis , surgery , carcinoma , oncology , cancer , disease
Objectives To evaluate the efficacy of targeted therapy after complete resection of metastatic lesions in patients with metastatic renal cell carcinoma. Methods We retrospectively reviewed the medical records of 53 patients with metastatic renal cell carcinoma who underwent complete surgical resection of metastatic lesions between J anuary 2006 and D ecember 2012. Immediate postoperative targeted therapy was given to a subgroup of patients. Progression‐free survival and cancer‐specific survival were assessed. Results All patients underwent curative surgery for a primary tumor. A total of 13 patients (24.5%) had metastatic disease at initial diagnosis, and 49 (92.5%) had single‐organ involvement at the time of first metastasis. None of the patients met the poor‐risk criteria. Of the 19 patients who received immediate postoperative targeted therapy, five (26.3%) experienced relapse. Of the 34 patients who did not receive immediate postoperative targeted therapy, 27 (79.4%) experienced disease recurrence. Targeted therapy was restarted in 30 patients (93.8%) after relapse with excellent disease control rates (complete response: 3.3%, partial response: 36.7%, stable disease: 46.7%). Immediate postoperative targeted therapy was associated with better median progression‐free survival (not reached vs 20.0 months; P = 0.017), but not better cancer‐specific survival. Conclusions Postoperative targeted therapy after complete metastasectomy seems to be associated with better progression‐free survival in patients with metastatic renal cell carcinoma, but not with cancer‐specific survival.